Literature DB >> 18547616

Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.

Frederique Penault-Llorca1, Catherine Abrial, Ines Raoelfils, Anne Cayre, Marie-Ange Mouret-Reynier, Marianne Leheurteur, Xavier Durando, Jean-Louis Achard, Pierre Gimbergues, Philippe Chollet.   

Abstract

Pathologic complete response (pCR) is linked to a better outcome, but its definition varies among working groups. We performed this study to validate different expressions of pCR as well as to determine the role of in situ and isolated tumor cell residues. A pathologic review was conducted on 710 operable patients with breast cancer to assess the residual disease in breast and in nodes according to the Chevallier (Ch) and Sataloff's (Sa) classifications. The pCR rate was 14.3% according to the Chevallier and 25.8% according to the Sataloff's classification. Overall survival and disease-free survival have been compared according to the pathologic response. There were significant differences between the pCR Ch(1+2) or Sa(A) and the non-pCR group. No significant difference was found between classes Ch(1) versus Ch(2) and between class Sa(A) without isolated cells versus class Sa(A) with isolated cells. Conversely, tumors histologically modified by chemotherapy were associated with a better prognosis than unmodified tumors. Finally, evidence of pCR in nodes was associated with a better prognosis. pCR should be defined as an absence of node invasion, and in the breast, either absence of tumor or tumor residue less than 5% of the tumor.

Entities:  

Mesh:

Year:  2008        PMID: 18547616     DOI: 10.1016/j.humpath.2007.11.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  22 in total

Review 1.  Biomarkers of residual disease after neoadjuvant therapy for breast cancer.

Authors:  Frederique Penault-Llorca; Nina Radosevic-Robin
Journal:  Nat Rev Clin Oncol       Date:  2016-02-09       Impact factor: 66.675

2.  Time to initiation of neo-adjuvant chemotherapy for breast cancer treatment does not influence patient survival: A study of US breast cancer patients.

Authors:  Devon Livingston-Rosanoff; Bret Hanlon; Nicholas Marka; Kara Vande Walle; Trista Stankowski-Drengler; Jessica Schumacher; Caprice C Greenberg; Heather Neuman; Lee G Wilke
Journal:  Breast J       Date:  2019-09-12       Impact factor: 2.431

3.  Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients.

Authors:  Devon Livingston-Rosanoff; Jessica Schumacher; Kara Vande Walle; Trista Stankowski-Drengler; Caprice C Greenberg; Heather Neuman; Lee G Wilke
Journal:  Clin Breast Cancer       Date:  2019-06-06       Impact factor: 3.225

4.  Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.

Authors:  Elena Provenzano; Veerle Bossuyt; Giuseppe Viale; David Cameron; Sunil Badve; Carsten Denkert; Gaëtan MacGrogan; Frédérique Penault-Llorca; Judy Boughey; Giuseppe Curigliano; J Michael Dixon; Laura Esserman; Gerd Fastner; Thorsten Kuehn; Florentia Peintinger; Gunter von Minckwitz; Julia White; Wei Yang; W Fraser Symmans
Journal:  Mod Pathol       Date:  2015-07-24       Impact factor: 7.842

5.  Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.

Authors:  Laura M Spring; Geoffrey Fell; Andrea Arfe; Lorenzo Trippa; Aditya Bardia; Chandni Sharma; Rachel Greenup; Kerry L Reynolds; Barbara L Smith; Brian Alexander; Beverly Moy; Steven J Isakoff; Giovanni Parmigiani
Journal:  Clin Cancer Res       Date:  2020-02-11       Impact factor: 12.531

Review 6.  Sentinel lymph nodes for breast carcinoma: an update on current practice.

Authors:  Aoife Maguire; Edi Brogi
Journal:  Histopathology       Date:  2016-01       Impact factor: 5.087

7.  A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial.

Authors:  E Provenzano; A-L Vallier; R Champ; K Walland; S Bowden; A Grier; N Fenwick; J Abraham; M Iddawela; C Caldas; L Hiller; J Dunn; H M Earl
Journal:  Br J Cancer       Date:  2013-01-08       Impact factor: 7.640

Review 8.  Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.

Authors:  Gaëtan Devos; Wout Devlies; Gert De Meerleer; Marcella Baldewijns; Thomas Gevaert; Lisa Moris; Daimantas Milonas; Hendrik Van Poppel; Charlien Berghen; Wouter Everaerts; Frank Claessens; Steven Joniau
Journal:  Nat Rev Urol       Date:  2021-09-15       Impact factor: 14.432

9.  Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.

Authors:  Hee Jin Lee; In Ah Park; In Hye Song; Sung-Bae Kim; Kyung Hae Jung; Jin-Hee Ahn; Sei-Hyun Ahn; Hak Hee Kim; Gyungyub Gong
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

10.  Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer.

Authors:  Yue Zhao; Xiaoqiu Dong; Rongguo Li; Xiao Ma; Jian Song; Yingjie Li; Dongwei Zhang
Journal:  Onco Targets Ther       Date:  2015-06-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.